Needham: Reiterates Pacira BioSciences (PCRX.US) rating and adjusted from buy to buy rating, target price is $45.00.
Zhitong FinanceApr 9 18:27
Pacira BioSciences Analyst Ratings
BenzingaApr 9 18:15
Pacira BioSciences Analyst Ratings
BenzingaMar 7 18:00
Pacira BioSciences Analyst Ratings
BenzingaMar 4 20:01
RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating
MT NewswiresMar 1 21:08
Pacira BioSciences Analyst Ratings
BenzingaMar 1 18:28
Pacira BioSciences Analyst Ratings
BenzingaFeb 8 21:30
RBC Cuts Price Target on Pacira BioSciences to $53 From $58, Keeps Outperform Rating
MT NewswiresJan 3 21:06
Raymond James Initiates Coverage On Pacira BioSciences With Outperform Rating, Announces Price Target of $42
BenzingaDec 20, 2023 19:31
Pacira BioSciences Analyst Ratings
BenzingaDec 20, 2023 19:30
HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $57
BenzingaNov 6, 2023 19:32
Pacira BioSciences Analyst Ratings
BenzingaNov 4, 2023 03:14
RBC Cuts Price Target on Pacira BioSciences to $58 From $67, Keeps Outperform Rating
MT NewswiresNov 3, 2023 20:05
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $45
BenzingaNov 3, 2023 18:42
Pacira BioSciences Analyst Ratings
BenzingaNov 3, 2023 18:40
Barclays Maintains Overweight on Pacira BioSciences, Lowers Price Target to $57
BenzingaOct 23, 2023 23:09
Pacira BioSciences Analyst Ratings
BenzingaOct 23, 2023 22:43
RBC Capital Reiterates Outperform on Pacira BioSciences, Maintains $68 Price Target
BenzingaOct 3, 2023 22:57
Pacira BioSciences Analyst Ratings
BenzingaOct 3, 2023 22:56
Wedbush Lowers Pacira BioSciences' Price Target to $57 From $60, Keeps Outperform Rating
MT NewswiresAug 4, 2023 19:07
No Data
No Data